Chilton Capital Management LLC Has $2.76 Million Stake in AbbVie Inc. (NYSE:ABBV)

Chilton Capital Management LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 1.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,163 shares of the company’s stock after selling 244 shares during the period. Chilton Capital Management LLC’s holdings in AbbVie were worth $2,758,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Pure Portfolios Holdings LLC acquired a new stake in shares of AbbVie in the first quarter valued at approximately $224,000. Tradewinds LLC. increased its stake in shares of AbbVie by 4.4% during the first quarter. Tradewinds LLC. now owns 11,714 shares of the company’s stock worth $2,454,000 after purchasing an additional 490 shares during the period. Jackson Wealth Management LLC increased its stake in AbbVie by 37.1% during the 1st quarter. Jackson Wealth Management LLC now owns 43,678 shares of the company’s stock worth $9,151,000 after acquiring an additional 11,825 shares during the period. McGlone Suttner Wealth Management Inc. increased its stake in AbbVie by 8.0% during the 1st quarter. McGlone Suttner Wealth Management Inc. now owns 11,044 shares of the company’s stock worth $2,314,000 after acquiring an additional 818 shares during the period. Finally, Lee Danner & Bass Inc. increased its stake in AbbVie by 0.7% during the 1st quarter. Lee Danner & Bass Inc. now owns 19,693 shares of the company’s stock worth $4,126,000 after acquiring an additional 136 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. BNP Paribas upgraded AbbVie to a “hold” rating in a research note on Thursday, May 8th. Evercore ISI lifted their price target on AbbVie from $204.00 to $205.00 and gave the company an “outperform” rating in a research note on Monday, April 28th. Citigroup lifted their price target on AbbVie to $205.00 and gave the company a “hold” rating in a research note on Wednesday, June 11th. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Finally, Erste Group Bank upgraded AbbVie to a “strong-buy” rating in a research note on Monday, March 17th. Eight analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $211.29.

AbbVie Stock Down 0.7%

Shares of NYSE:ABBV opened at $189.50 on Friday. The company has a market capitalization of $334.73 billion, a price-to-earnings ratio of 80.64, a P/E/G ratio of 1.26 and a beta of 0.48. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64. The business’s 50-day moving average is $187.37 and its 200-day moving average is $188.56. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $218.66.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.40 by $0.06. The company had revenue of $13.34 billion for the quarter, compared to the consensus estimate of $12.91 billion. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The firm’s revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.31 EPS. Equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be paid a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.46%. The ex-dividend date is Tuesday, July 15th. AbbVie’s dividend payout ratio is 279.15%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.